切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2021, Vol. 14 ›› Issue (04): 536 -538. doi: 10.3877/cma.j.issn.1674-6902.2021.04.039

综述 上一篇    下一篇

晚期非小细胞肺癌免疫治疗预测生物标志物的研究进展
农靖颖 1, 顾艳斐 2, 张毅 1 , ( )   
  1. 1. 100053 北京,首都医科大学宣武医院胸外科国家老年疾病临床医学研究中心肿瘤诊疗中心、首都医科大学肺癌诊疗中心
    2. 100015 北京,北京和睦家医院启望肿瘤中心肿瘤内科
  • 收稿日期:2021-03-08 出版日期:2021-08-25
  • 通信作者: 张毅

Research progress on biomarkers for immunotherapy prediction of advanced non­small cell lung cancer

Jingying Nong 1, Yanfei Gu 2, Yi Zhang 1( )   

  • Received:2021-03-08 Published:2021-08-25
  • Corresponding author: Yi Zhang
1
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2
Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study[J]. J Clin Oncol, 2019, 37(28): 2518-2527.
3
Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830.
4
Spigel D., de Marinis, Giaccone, et al. LBA78-IMpower110: Interim overall survival (OS) analysis of a phase Ⅲ study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC[J] . Annal Oncol, 30( Supplement 5): v915.
5
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
6
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
7
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846.
8
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265.
9
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550.
10
West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937.
11
Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and Nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase Ⅲ trial[J]. J Thorac Oncol, 2020, 15(8): 1351-1360.
12
Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
13
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051.
14
Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(14): 1505-1517.
15
Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407[J]. J Thorac Oncol, 2020, 15(10): 1657-1669.
16
Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301.
17
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell[J]. Lung Cancer, 2019, 381(21): 2020-2031.
18
Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project[J]. J Thorac Oncol, 2018, 13(9): 1302-1311.
19
Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2): 208-222.
20
Lee HH, Wang YN, Xia W, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy[J]. Cancer Cell, 2019, 36(2): 168-178 e164.
21
Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8): 1321-1328.
22
Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.
23
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128.
24
Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9): 1441-1448.
25
Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel[J]. JAMA Oncol, 2019, 5(5): 696-702.
26
J. Chen HY, Song Y., Cui L., et al. FGFR1-4 mutations are associated with immunotherapy outcomes in patients with non-small cell lung cancer[J]. Annal Oncol, 2020, 31(suppl_4): S1018-S1025.
[1] 王鲲鹏, 袁逸杰, 朱嘉琪, 张婷婷. LIN9基因在宫颈癌细胞中表达及其与人乳头瘤病毒16/18 E7表达的相关性[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(03): 196-201.
[2] 王俊旗, 徐锋. 程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展[J]. 中华普通外科学文献(电子版), 2021, 15(04): 304-308.
[3] 汤俊, 刘占伟, 石明宏. 奥希替尼放疗对EGFR突变阳性NSCLC的临床分析[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 481-483.
[4] 周昌冬, 左小华, 单奔, 戚云凤. 血清miR-210、CY21-1联合多层螺旋CT诊断早期非小细胞肺癌临床意义[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 489-492.
[5] 郑贝贝, 朱诺, 杨玖. EGFR-TKI联合胸部三维放疗治疗Ⅳ期非小细胞肺癌疗效分析[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 511-513.
[6] 曹路, 高宝安, 官莉, 陈世雄. 受体相互作用蛋白激酶4蛋白在组织中的表达NSCLC及其临床病理特征[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 517-519.
[7] 张倩, 高永恒, 郑开福, 金发光. 新辅助免疫治疗在手术可切除非小细胞肺癌中的研究进展[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 533-535.
[8] 陈燏, 王玉秀, 闵凌峰. NIX蛋白表达与非小细胞肺癌临床病理特征及预后[J]. 中华肺部疾病杂志(电子版), 2021, 14(04): 412-416.
[9] 蒋雪, 刘恒, 何伟, 傅莉. 食道癌并发肺转移40例临床特征分析[J]. 中华肺部疾病杂志(电子版), 2021, 14(03): 363-365.
[10] 严锡祥, 郑爱东, 张振恩, 潘国翠, 崔永华. 胸腺肽α1免疫治疗联合抗感染对重症肺部感染的影响[J]. 中华肺部疾病杂志(电子版), 2021, 14(03): 301-304.
[11] 杨永生, 方荣焕. 胆管癌免疫微环境及免疫治疗[J]. 中华肝脏外科手术学电子杂志, 2021, 10(04): 360-364.
[12] 朱曙光, 陈健宁, 李海波, 邱春辉, 叶林森, 代天星, 李华, 汪国营. 免疫治疗联合靶向药物治疗复发性肉瘤样肝细胞癌疗效[J]. 中华肝脏外科手术学电子杂志, 2021, 10(04): 409-413.
[13] 张旋, 武涛, 李进莎, 李国钰, 李权, 董超, 李婷, 杨仁芳, 李云峰. 新辅助免疫治疗:dMMR/MSI-H局部进展期结直肠癌患者的“黎明之光”[J]. 中华结直肠疾病电子杂志, 2021, 10(04): 404-408.
[14] 薛兴阳, 蓝永权, 丁丹丹, 吴华振, 罗志明, 赵健. FOXA1在非小细胞肺癌组织中的表达及与癌转移相关性研究[J]. 中华临床实验室管理电子杂志, 2021, 09(03): 150-153.
[15] 徐韫健, 王建平, 林勇平, 姜桔红. 小体积核酸样本检测晚期非小细胞肺癌患者外周血表皮生长因子受体突变的可行性及应用[J]. 中华临床实验室管理电子杂志, 2021, 09(03): 164-168.
阅读次数
全文


摘要